Reviva Pharmaceuticals Files Q1 2025 10-Q

Ticker: RVPH · Form: 10-Q · Filed: May 15, 2025

Sentiment: neutral

Topics: 10-Q, pharmaceuticals, financials

TL;DR

Reviva Pharma's Q1 2025 10-Q is in. Check financials.

AI Summary

Reviva Pharmaceuticals Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and operational updates for the first quarter of 2025. The company, formerly Tenzing Acquisition Corp., is based in Cupertino, CA.

Why It Matters

This filing provides investors with the latest financial performance and disclosures for Reviva Pharmaceuticals, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Reviva is subject to significant regulatory, clinical, and market risks inherent in drug development and commercialization.

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is the quarter ended March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 15, 2025.

What was Reviva Pharmaceuticals Holdings, Inc. formerly known as?

Reviva Pharmaceuticals Holdings, Inc. was formerly known as Tenzing Acquisition Corp.

Where is Reviva Pharmaceuticals Holdings, Inc. located?

Reviva Pharmaceuticals Holdings, Inc. is located at 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014.

What is the Standard Industrial Classification code for Reviva Pharmaceuticals?

The Standard Industrial Classification code for Reviva Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).

View full filing on EDGAR

View on Read The Filing